💊 Torrent Pharma (CMP ₹3,685, +1%) – Short & Long Term View

📊 Technical View 📊 Technical Setup Stock trending in a rising channel, holding above 20 & 50 DMA → bullish. RSI ~62 → positive momentum, not overbought. Supports: ₹3,600 / ₹3,520. Resistances: ₹3,750–3,780, then ₹3,950–4,000. 🎯 Short-term targets (2–4 wks): ₹3,750 / ₹3,880 / ₹4,000. 🎯 Long-term targets (6–12 mths): ₹4,400 / ₹4,800. 📈 Fundamentals Among India’s top pharma firms with strong branded generics in India, Brazil, Germany & US. Strength in cardiac, CNS, gastro & anti-diabetic segments drives steady growth. Recent Q1 showed stable revenue, margin improvement, R&D expansion. Healthy balance sheet post fundraise; exports in US & Brazil expected to accelerate. ⭐ Analyst View Consensus rating: BUY/ACCUMULATE. Short-term targets: ₹3,900–₹4,200. Long-term: ₹4,600–₹5,000. Positive view on domestic leadership + global expansion. ⚠️ Risks USFDA & regulatory issues could impact exports. Price control in India (NLEM) may pressure margins. High competition in generics vs Sun Pharma, Cipla, Dr. Reddy’s. Currency fluctuations (USD, BRL, EUR) add volatility. ✅ Summary Torrent Pharma is a structurally strong pharma play with technical breakout signals and robust fundamentals. Short-term upside toward ₹3,880–₹4,000, long-term potential up to ₹4,800. Bias stays bullish above ₹3,600